Artificial Intelligence–Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration

Topic: Amyloid, tau and blood-test diagnosis

Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. However, their use has increased the importance of detecting and monitoring amyloid-related imaging abnormalities (ARIA) on MRI, as such findings may influence treatment continuation, dose modification, and patient safety assessment. As anti-amyloid therapies expand into routine practice, increasing surveillance MRI volumes, interreader variability, and the potential for missed subtle abnormalities have generated interest in artificial intelligence (AI)-based clinical decision support tools. A multidisciplinary panel of neuroradiologists and Alzheimer disease clinicians examined the extent of evidence supporting clinical implementation of AI-assisted ARIA detection tools, these tools' safe integration into practice, and remaining evidence gaps. The panel concluded that AI-assisted ARIA detection is likely to enhance patient safety when used as clinical decision support within a radiologist-in-the-loop framework. Panelists also noted substantial variation among commercially available tools in regulatory status, technical capabilities, and validation evidence. Moreover, they emphasized the need for further studies to assess the impact of improved detection on clinical outcomes. Overall, the panel supported conditional implementation with radiologist oversight, ongoing quality assurance, and prospective monitoring of clinical performance.

Key findings

• The panel concluded that AI-assisted ARIA detection is likely to enhance patient safety when used as clinical decision support within a radiologist-in-the-loop framework.
• Overall, the panel supported conditional implementation with radiologist oversight, ongoing quality assurance, and prospective monitoring of clinical performance.

Why it matters

A panel of experts concluded that AI-assisted detection of ARIA on MRI is likely to improve patient safety when used as decision support with a radiologist still reviewing the scans. They supported only conditional use with radiologist oversight, ongoing quality assurance, and prospective monitoring, and noted that more studies are needed to show whether better detection actually improves patient outcomes.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.2214/ajr.26.35514
• PubMed: 42747213
• Original source →
• Free full text: UCL Discovery (University College London) →

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

@article{petrella2026-42747213,
  author  = {Petrella, Jeffrey R. and Barkhof, Frederik and Benzinger, Tammie L.S. and Cogswell, Petrice M. and Franceschi, Ana Marija and Sabbagh, Marwan Noel and Salloway, Stephen and Zaharchuk, Greg and others},
  title   = {{Artificial Intelligence–Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration}},
  journal = {American Journal of Roentgenology},
  year    = {2026},
  doi     = {10.2214/ajr.26.35514},
  pmid    = {42747213},
  url     = {https://doi.org/10.2214/ajr.26.35514}
}

Related studies in Treatments

• Artificial Intelligence–Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls American Journal of Neuroradiology · 2025-07-30 · usefulness score 42/100
• Artificial Intelligence in Alzheimer’s Disease: Evidence Maturity and Clinical Translation Across the Care Pathway Preprints.org · 2026-07-30 · usefulness score 16/100
• Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model BMC medicine · 2022-02-01 · usefulness score 59/100
• Use of Artificial Intelligence in Imaging Dementia Cells · 2024-11-27 · usefulness score 45/100
• The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study European radiology · 2017-09-27 · usefulness score 69/100
• Real-World Challenges in the MRI Detection and Classification of Amyloid-Related Imaging Abnormalities American Journal of Roentgenology · 2026-09-02 · usefulness score 44/100

Similar studies

• Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Therapies for Alzheimer's Disease: An Update from the Alzheimer's Association ARIA Workgroup 2026 · Treatments
• The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease 2025 · Digital health tools
• Artificial intelligence in brain MRI analysis of Alzheimer's disease over the past 12 years: A systematic review 2022 · Digital health tools
• Artificial intelligence for drug discovery and development in Alzheimer's disease 2024 · Digital health tools
• AI-Driven Alzheimer’s Detection Performance Analysis of Pretrained CNN Models on MRI Data 2025 · Brain scans and imaging
• Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease 2024 · Digital health tools

More on Treatments

• A review that covers this ground Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy The journal of prevention of Alzheimer's disease · 2022-01-01 · usefulness score 40/100
• Newest in this subject Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling Research Square · 2026-10-20 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Treatments →